Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis

• Status: Active, not recruiting
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Both gender, 19 years ≤ age ≤ 80 years

• Bronchitis Severity Score* ≥ 5point at Visit 2 (Randomized Visit)

• Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)

• Those who can comply with the requirements of clinical trials

• Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

• Patients who investigators determines to severe respiratory disease that would interfere with study assessment

• Patients with systemic infections requiring systemic antibiotic therapy

• patient with hemostatic disorder